For the Inventor, By the Inventor

Enter assignee name

Coinsins, Switzerland

Merck Serono S. a.

USPTO Granted Patents = 145

% Expired Patents = 66.2

CIPO Patents = 36

EPO Patents = 105

Forward Citations = 401

Loading Chart...

Loading Chart...

193 inventors (with patents filed for the assignee):

Anna Quattropani (25 out of 58 patents)

Matthias Schwarz (23 out of 35 patents)

Thomas Rueckle (16 out of 21 patents)

4. Agnes Bombrun (15 out of 24 patents)

5. Vincent Pomel (13 out of 22 patents)

6. Catherine Jorand-Lebrun (12 out of 23 patents)

7. Jerome Dorbais (12 out of 14 patents)

8. Dominique Swinnen (11 out of 24 patents)

9. Stefano Crosignani (10 out of 23 patents)

10. Dennis Church (10 out of 18 patents)

11. Andreas Goutopoulos (9 out of 50 patents)

12. Xuliang Jiang (9 out of 19 patents)

13. Patrick Gerber (9 out of 14 patents)

14. Jerome Gonzalez (9 out of 11 patents)

15. David Covini (9 out of 9 patents)

Core Competencies:

Cladribine

Monoclonal Antibodies

IL-31

Multiple Sclerosis

Antibody Formulations

Vascular Diseases

Protein Production

S1P Receptor

Thiazole Derivatives

JNK Inhibitors

Cancer Treatments

Autoimmune Diseases

145 patents: Sort by Forward Citations

1. 12377056 - Cladribine regimen for treating multiple sclerosis (2025-08-05),

2. 11542327 - Methods of treating pruritic disease with IL-31 monoclonal antibodies (2023-01-03),

3. 11524031 - Use of a combination of D-aspartic and L-aspartic acids or salts thereof for the treatment of male infertility (2022-12-13),

4. 11513120 - Membrane bound reporter molecules and their use in cell sorting (2022-11-29),

5. 10640559 - Nucleic acid molecules encoding humanized IL-31 monoclonal antibodies (2020-05-05),

6. 10555913 - Cladribine regimen for treating multiple sclerosis (2020-02-11),

7. 10342826 - Use of a combination of D-aspartic and L-aspartic acids or salts thereof for the treatment of male infertility (2019-07-09),

8. 10259795 - Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof (2019-04-16),

9. 9982044 - Method of treating pruritus with IL-31 monoclonal antibody formulations (2018-05-29),

10. 9925151 - Cladribine regimen for treating multiple sclerosis (2018-03-27),

11. 9834528 - Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof (2017-12-05),

12. 9738715 - IL-31 monoclonal antibody formulations (2017-08-22),

13. 9592267 - Use of IL-18BP for treatment of peripheral vascular diseases (2017-03-14),

14. 9574003 - Low fucose cell lines and uses thereof (2017-02-21),

15. 9567398 - Antibody with specificity for GM-CSF (II) (2017-02-14),

Company Overview

Merck Serono S.A., headquartered in Coinsins, Switzerland, is a prominent player in the biopharmaceutical sector, specializing in the development and production of monoclonal antibodies. The company focuses on innovative treatments for conditions such as multiple sclerosis and vascular diseases, leveraging advanced technologies in protein production and antibody formulations. With a commitment to addressing unmet medical needs, Merck Serono is dedicated to enhancing patient outcomes through its cutting-edge research in immunology and related fields.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

145 Patents

#1 in Coinsins

#125 in Switzerland

#5,622 in the World

Coinsins, Switzerland

Merck Serono S. a.

Forward Citations = 401

193 inventors:

Anna Quattropani (25 out of 58 patents)

Matthias Schwarz (23 out of 35 patents)

Thomas Rueckle (16 out of 21 patents)

4. Agnes Bombrun (15 out of 24 patents)

5. Vincent Pomel (13 out of 22 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Merck Serono S. a.. Retrieved from https://idiyas.com/company/merck-serono-s-a

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…